Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
French long-term extension study of teriflunomide in clinically isolated syndrome
2015-002298-39Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teriflunomide in clinically isolated syndrome (CIS) and multiple sclerosis (MS), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Long-term safety and tolerability of teriflunomide 14 mg per day. Started Sep 2015; status: completed.
02
Drugs
teriflunomide
03
Conditions
clinically isolated syndrome (CIS)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2015-002298-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002298-39.